Table 2

Data During Normal and Elevated Afterload: Clinical Study

Control Subjects (n = 11)LBBB Patients (n = 11)ANOVA
BaselineElevated AfterloadBaselineElevated Afterload
Heart rate, beats/min68 ± 1088 ± 1369 ± 1192 ± 16NS
Systolic blood pressure, mm Hg137 ± 23175 ± 28135 ± 16169 ± 23NS
Diastolic blood pressure, mm Hg79 ± 7103 ± 1077 ± 7103 ± 13NS
LV end-diastolic volume, ml101 ± 1999 ± 24111 ± 25111 ± 21NS
LV end-systolic volume, ml40 ± 1046 ± 1549 ± 1263 ± 14p < 0.01
LV stroke volume, ml61 ± 1053 ± 1362 ± 1747 ± 12NS
LV ejection fraction, %60 ± 454 ± 656 ± 642 ± 7p < 0.01
Global longitudinal shortening, %20.8 ± 2.518.4 ± 2.417.1 ± 2.212.4 ± 1.8p < 0.01
Septal systolic shortening, %18.3 ± 2.614.7 ± 3.111.7 ± 3.86.3 ± 4.6NS
LV lateral wall systolic shortening, %18.4 ± 3.916.7 ± 3.616.7 ± 3.713.6 ± 5.6NS
Septal work, mm Hg·%4,521 ± 1,1794,819 ± 1,4672,236 ± 6,931,107 ± 856p < 0.01
LV lateral wall work, mm Hg·%4,048 ± 8985,206 ± 1,8494,113 ± 9374,474 ± 1,290NS

Values are mean ± SD.

ANOVA = analysis of variance; NS = nonsignificant; other abbreviations as in Table 1.

  • p < 0.05 vs. normal afterload.

  • p < 0.05 vs. control subjects. ANOVA refers to the interaction effect from a mixed between-within subjects ANOVA.